Experigen Management Company

Experigen Management Company, primarily operating as Metro International Biotech, is a clinical-stage biotechnology company focused on developing small molecule therapies that modulate nicotinamide adenine dinucleotide (NAD+) levels. The company targets the underlying mechanisms of aging and mitochondrial dysfunction to treat a variety of rare and age-related diseases. Its lead candidate, MIB-626, is a proprietary crystalline form of nicotinamide mononucleotide (NMN) currently being evaluated in Phase 2 clinical trials for indications such as Friedreich's ataxia and Alzheimer's disease. Co-founded by Dr. David Sinclair, a leading expert in longevity science, the company leverages a deep understanding of sirtuin biology and metabolic health. Experigen operates as part of the Life Biosciences family of companies, aiming to translate breakthrough aging research into transformative medicines.